Deuruxolitinib phosphate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for deuruxolitinib phosphate and what is the scope of freedom to operate?
Deuruxolitinib phosphate
is the generic ingredient in one branded drug marketed by Sun Pharm Inds Inc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Deuruxolitinib phosphate has twenty-four patent family members in thirteen countries.
Summary for deuruxolitinib phosphate
| International Patents: | 24 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 2 |
| DailyMed Link: | deuruxolitinib phosphate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for deuruxolitinib phosphate
Generic Entry Date for deuruxolitinib phosphate*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for deuruxolitinib phosphate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Concert Pharmaceuticals | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for deuruxolitinib phosphate
US Patents and Regulatory Information for deuruxolitinib phosphate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | LEQSELVI | deuruxolitinib phosphate | TABLET;ORAL | 217900-001 | Jul 25, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sun Pharm Inds Inc | LEQSELVI | deuruxolitinib phosphate | TABLET;ORAL | 217900-001 | Jul 25, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sun Pharm Inds Inc | LEQSELVI | deuruxolitinib phosphate | TABLET;ORAL | 217900-001 | Jul 25, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for deuruxolitinib phosphate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Mexico | 2021014175 | TRATAMIENTO DE TRASTORNOS DE PERDIDA DE CABELLO CON INHIBIDORES DE CINASAS ASOCIADAS A JANUS (JAK) DEUTERADOS. (TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS.) | ⤷ Sign Up |
| Mexico | 2023002325 | TRATAMIENTO DE TRASTORNOS DE PERDIDA DE CABELLO CON INHIBIDORES DE CINASAS ASOCIADAS A JANUS (JAK) DEUTERADOS. (TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS.) | ⤷ Sign Up |
| Mexico | 2018013347 | TRATAMIENTO DE TRASTORNOS DE PÉRDIDA DE CABELLO CON INHIBIDORES DE CINASAS ASOCIADAS A JANUS (JAK) DEUTERADOS. (TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS.) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
